Advertisement

Rationale of Combined Chemotherapy of Brain Tumours

  • J. Hildebrand
  • D. Zegers de Beyl

Abstract

In this review dealing with the rationale for combination chemotherapy of brain tumours, two main issues will be considered: (a) what are the characteristics of brain tumours most likely to determine the choice of chemotherapeutic drugs, and (b) is there any clinical evidence supporting the view that combination chemotherapy is superior to single-drug therapy in human brain neoplasms.

Keywords

Brain Tumour Malignant Glioma Malignant Brain Tumour Growth Fraction Combine Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Blasberg, R., Patlack, C., Shapiro, W., Fenstermacher, J.: Metastatic brain tumours: local blood flow and capillary permeability. Neurology 29, 547, 1979Google Scholar
  2. 2.
    EORTC brain tumour group: Effect of CCNU on survival, rate of objective remission and duration of free interval in patients with malignant brain glioma: final evaluation. Europ. J. Cancer 14, 851–856, 1978Google Scholar
  3. 3.
    EORTC brain tumour group: Evaluation of the CCNU, VM26 plus CCNU and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. J. Neurosurg. 55, 27–31, 1981CrossRefGoogle Scholar
  4. 4.
    Fewer, D., Wilson, C. B., Boldrey, E. B., Enot, K. J., Powell, M. R.: The chemotherapy of brain tumours: clinical experience in the carmustine (BCNU) and vincristine. JAMA 222, 544–559, 1972CrossRefGoogle Scholar
  5. 5.
    Hildebrand, J., Nouwynck, C.: Malignant gliomas. In: Randomized trials in cancer, a critical review by sites. M. J. Staquet (ed.), pp. 377–388. New York: Raven Press 1978Google Scholar
  6. 6.
    Hoshino, T., Barker, M., Wilson, C. B.: The kinetics of cultured human glioma cells. Acta Neuropathol. 32, 235–244, 1975PubMedCrossRefGoogle Scholar
  7. 7.
    Levin, V. A., Patlack, C. S., Landahl, H. D.: Heuristic modelling of drug delivery to malignant brain tumour. J. Pharmacokinet. Biopharm. 8, 257–296 (1980)PubMedCrossRefGoogle Scholar
  8. 8.
    Long, J. M.: Capillary ultrastructure and blood-brain barrier in human brain tumours. J. Neurosurg. 32, 127–144, 1970PubMedCrossRefGoogle Scholar
  9. 9.
    Neuwelt, E. A., Diehl, J. T., Long, H. W., Hill, R. N., Michael, A. J., Frenkel, E. P.: Monitoring of methotrexate delivery in patients with malignant brain tumours after osmotic blood-brain barrier disruption. Ann. Intern. Med. 94, 449–454, 1981PubMedGoogle Scholar
  10. 10.
    Norell, H., Wilson, C. B., Slagel, D. E., Clark, D. B.: Leukoencephalopathy following the administration of methotrexate in the cerebrospinal fluid in treatment of primary brain tumours. Cancer 33, 923–932, 1974CrossRefGoogle Scholar
  11. 11.
    Shapiro, W. R., Chernik, N. L., Posner, J. B.: Necrotizing encephalopathy following intraventricular instillation of methotrexate. Arch. Neurol. 28, 96–102, 1973PubMedCrossRefGoogle Scholar
  12. 12.
    Shapiro, J. R., Yung, A., Wei-Kwan, Shapiro, W. R.: Isolation, karyotype and clonal growth of heterogeneous subpopulation of human malignant gliomas. Cancer Res. 41, 2349–2359, 1981PubMedGoogle Scholar
  13. 13.
    van Putten, L. M., Keizer, H. J., Mulder, J. H.: Syndromization in tumour chemotherapy. Europ. J. Cancer 12, 79–85, 1976Google Scholar
  14. 14.
    Wilson, C. B., Gutin, P., Boldrey, E. B., Crafts, D., Levin, V. A., Enot, J.: Single agent chemotherapy of brain tumours. Arch. Neurol. 33, 739–144, 1976PubMedCrossRefGoogle Scholar
  15. 15.
    Wilson, C. B., Yorke, C. H. Jr., Levin, V. A.: Intracranial malignant growth, primary and metastatic. In: Current problems in cancer. R. C. Hickey (ed.), Year Book Medical Publishers, Vol. I, Nr. 8, 1977Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1982

Authors and Affiliations

  • J. Hildebrand
  • D. Zegers de Beyl

There are no affiliations available

Personalised recommendations